You are here

  • Home
  • Archive
  • Volume 9, Issue 12
  • Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)

 

Online download statistics by month:

Online download statistics by month: December 2021 to February 2026

AbstractFullPdf
Dec 2021330332190
Jan 2022261264148
Feb 202217117246
Mar 202216016071
Apr 202212412681
May 2022143146111
Jun 202210210339
Jul 202210310440
Aug 202211711862
Sep 202213413444
Oct 202216016580
Nov 2022118120100
Dec 2022787945
Jan 2023555534
Feb 2023646445
Mar 2023727353
Apr 2023717166
May 2023697052
Jun 2023535346
Jul 2023525249
Aug 2023626243
Sep 2023525334
Oct 2023636340
Nov 2023585935
Dec 2023727247
Jan 2024727344
Feb 2024606044
Mar 2024787884
Apr 2024787967
May 2024868860
Jun 2024747670
Jul 2024818258
Aug 2024545547
Sep 2024535355
Oct 2024919169
Nov 20249810067
Dec 2024157159112
Jan 2025788054
Feb 2025585845
Mar 2025777856
Apr 202511211363
May 2025798065
Jun 2025616340
Jul 2025110
Feb 2026110
Total419342382701